LILars Fogh Iversen

Lars Fogh Iversen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lars Fogh Iversen has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Behrend F. Lundt

    From the tOaProtein Chemistry, tOfDiabetes Biology, tOhNew Lead Discovery, tOjSignal Transduction, Novo Nordisk, DK-2880 Bagsvaerd, Denmark, tOdMed Chem Research I, tOgMed Chem Research IV, Novo Nordisk, DK-2760 Måløv Denmark, tOeDepartment of Chemistry, Technical University of Denmark, DK-2800 Lyngby, Denmark, and iOntogen Corporation, Carlsbad, California 92009

    1 shared publication
  • Claus Bekker Jeppesen

    From the tOaProtein Chemistry, tOfDiabetes Biology, tOhNew Lead Discovery, tOjSignal Transduction, Novo Nordisk, DK-2880 Bagsvaerd, Denmark, tOdMed Chem Research I, tOgMed Chem Research IV, Novo Nordisk, DK-2760 Måløv Denmark, tOeDepartment of Chemistry, Technical University of Denmark, DK-2800 Lyngby, Denmark, and iOntogen Corporation, Carlsbad, California 92009

    1 shared publication
  • F. C. Wiberg

    Novo Nordisk A/S, Novo Allé, DK‐2880 Bagsvaerd, Denmark

    1 shared publication
  • Günther Herbert Johannes Peters

    Technical University of Denmark

    1 shared publication
  • H. J. Flodgaard

    Novo Nordisk A/S, Novo Allé, DK‐2880 Bagsvaerd, Denmark

    1 shared publication
  • Henrik Sune Andersen

    From the tOaProtein Chemistry, tOfDiabetes Biology, tOhNew Lead Discovery, tOjSignal Transduction, Novo Nordisk, DK-2880 Bagsvaerd, Denmark, tOdMed Chem Research I, tOgMed Chem Research IV, Novo Nordisk, DK-2760 Måløv Denmark, tOeDepartment of Chemistry, Technical University of Denmark, DK-2800 Lyngby, Denmark, and iOntogen Corporation, Carlsbad, California 92009

    1 shared publication

Latest Publications

  • Open Access

    Structure-based Design of a Low Molecular Weight, Nonphosphorus, Nonpeptide, and Highly Selective Inhibitor of Protein-tyrosine Phosphatase 1B

    by Lars Fogh Iversen, Henrik Sune Andersen, Sven Branner, Steen B. Mortensen, Günther H. Peters, Kjeld Norris, Ole Hvilsted Olsen, Claus Bekker Jeppesen, Behrend F. Lundt, William Ripka, et al.


  • Open Access

    Structure and function of the N‐linked glycans of HBP/CAP37/azurocidin: Crystal structure determination and biological characterization of nonglycosylated HBP

    by L. F. Iversen, J. S. Kastrup, S. E. Bjørn, F. C. Wiberg, I. K. Larsen, H. J. Flodgaard, P. B. Rasmussen

    The three N‐glycosylation sites of human heparin binding protein (HBP) have been mutated to produce a nonglycosylated HBP (ng‐HBP) mutant. ng‐HBP has been crystallized and tested for biological activity. Complete X‐ray data have been collected to 2.1 Å resolution, and the structure has been fully refined to an R‐factor of 18.4% (Rfree 27.7%). The ng‐HBP structure reveals that neither the secondary nor tertiary structure have changed due to the removal of the glycosylation, as compared to the previously determined glycosylated HBP structure. Although the primary events in N‐linked glycosylation occurs concomitant with polypeptide synthesis and therefore possesses the ability to influence early events in protein folding, we see no evidence of glycosylation influencing the structure of the protein. The root‐mean‐square deviation between the superimposed structures was 0.24 Å (on Cα atoms), and only minor local structural differences are observed. Also, the overall stability of the protein seems to be unaffected by glycosylation, as judged by the B‐factors derived from the two X‐ray structures. The flexibility of a glycan site may be determined by the local polypeptide sequence and structure rather than the glycan itself. The biological in vitro activity assay data show that ng‐HBP, contrary to glycosylated HBP, mediates only a very limited stimulation of the lipopolysaccharide induced cytokine release from human monocytes. In animal models of fecal peritonitis, glycosylated HBP treatment rescues mice from and an otherwise lethal injury. It appears that ng‐HBP have significant effect on survival, and it can be concluded that ng‐HBP can stimulate the host defence machinery albeit to a lesser extent than glycosylated HBP.